O’Melveny Represents Brii Biosciences in US$318 Million Hong Kong IPO
July 13, 2021
FOR IMMEDIATE RELEASE
HONG KONG—JULY 13, 2021—O’Melveny recently represented Brii Biosciences Limited (2137.HK) in the HK$2.48 billion (US$318 million) IPO and listing on the Hong Kong Stock Exchange. Assuming full exercise of the over-allotment option, the offering size will be approximately HK$2.85 billion (US$366 million).
Founded in 2017, Brii Biosciences is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses.
Morgan Stanley, UBS, and CICC acted as joint global coordinators for the IPO. Cornerstone investors in Brii Biosciences include Invesco, UBS Asset Management (Singapore) Ltd. and RBC Global Asset Management (Asia) Limited, among others.
The O’Melveny team was led by partners Edwin Kwok, Kurt Berney, and Ke Geng, and included counsel Wenting Yu and Wendy Kan, associates Yuki Tsang and Qianru Hong, and trainee solicitor Julianna Chan.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com or learn more in our firm at-a-glance, year-end highlights, and on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
Contact:
Christopher Rieck
O’Melveny & Myers LLP
+1 212 326 2218
crieck@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com